FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of The Blacklisting of Peptides 503A vs. 503B Compounding Pharmacies Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # What is a 503B outsourcing facility, and why are so many of them uninspected by FDA? Partnership for Safe Medicines FDA Compliance for Peptide Therapy and BPC 157 Holt Law